AVEO Squeezes $81M Out of IPO Window; No Fools Rush in

BioWorld Online

And with good Phase III data and strong partnerships for bowel drug linaclotide, Ironwood's stock (NASDAQ:IRWD) has climbed about 15 percent above its ...

Aveo Pharmaceuticals 9M-Share IPO Priced At $9 Each Wall Street Journal

Biotechs Continue IPO March, Without Banging The Drums Wall Street Journal (blog)



all 215 news articles »

Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year 2009 Financial ...

MarketWatch (press release)

This increase is primarily due to increased activities associated with the initiation of the first of two NicVAX Phase III clinical trials. ...

Nabi Biopharmaceuticals logs revenue from Glaxo sale Bizjournals.com

Nabi Pharmaceuticals reports 4th-quarter profit on sale of PentaStaph to ... CanadianBusiness.com



all 34 news articles »

Patients With Benefit From Ustekinumab Treatment Up to 3 Years: Presented at AAD

DG News

Included in this data were 36 weeks of data from the C0379T04 placebo-controlled phase 2 trial, 76 weeks from the PHOENIX 1 phase 3 trial, and 52 weeks from ...



and more »

Delcath Systems Provides Update on Corporate Developments

PR Newswire (press release)

"The next operational milestone for our company is the April completion of data analysis from our Phase III trial," said Mr. Hobbs. ...



and more »

Financings of the Fortnight Checks the Rime of the Ancient Mariner

The in vivo blog (blog)

4 it would postpone because murky FDA guidance on antibiotic non-inferiority trials forced it to modify a Phase III trial. (Note that some of Trius's peers ...



and more »

Facet Biotech Wooed by $722M Acquisition Offer from Abbott

BioWorld Online

A Phase IIb monotherapy trial is under way, with data expected in the second half of 2011. A Phase III trial is slated to begin in the second quarter. ...

Abbott Labs to buy Facet Biotech for $722M Bizjournals.com

Abbott Bids 66% Premium for Facet's Drugs Barron's (blog)

Facet Biotech Stock Soars on Abbott Bid TheStreet.com

Pharma Times  - Wall Street Journal  - Zenopa

all 515 news articles »

Swiss stocks - Factors to watch on March 12

Reuters

Roche announced today the topline results of a phase III study, known as CALGB 90401, which did not meet its primary objective of extending overall survival ...

INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results ...

PR Newswire (press release)

PHOENIX, March 9 /PRNewswire/ -- INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the ...



and more »

Transgene's Licencing Deal With Novartis Disappoints

Wall Street Journal

Transgene said it will start global phase IIb and phase III clinical trials by the end of 2010, involving around 1000 patients. It expects phase IIb results ...



and more »

Investors Unfazed by Roche-Biogen Idec Testing Troubles

Seeking Alpha (blog)

PK) and Biogen Idec (BIIB) have suspended phase III trials of ocrelizumab in rheumatoid arthritis (RA) and lupus was the limited impact it had on the shares ...

Roche and Biogen Idec Put the Brakes on Development of Ocrelizumab in RA Genetic Engineering News (press release)

Pipeline Setback for Biogen Zacks.com

Roche, Biogen stop arthritis drug program San Francisco Business Times



all 214 news articles »

global markets: European Stocks Flat After Losing Early Gains

Wall Street Journal

The company's shares fell 1.5% after a Phase III trial showed its Recentin drug was no better than Roche's Avastin for treating colorectal cancer. ...

WSJ:European Stocks Close Mostly Flat As Greek Concerns Recede Wall Street Journal



all 1,444 news articles »

Alzheimer's Drug: Dimebon Is Down The Drain

Huffington Post (blog)

Results came from an FDA approved Phase III clinical trial named connection that was being run by Pfizer and its subsidiary company, Medivation. ...

Lesson from an Alzheimer-Drug Failure: Beware Russian Clinical Trial Data BNET

Disappointment at failure of Pfizer/Medivation's Alzheimer's drug Pharma Times



all 26 news articles »

BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III ...

MarketWatch (press release)

Therefore, in view of the DMC recommendation, the BioSante LibiGel Phase III development program will continue as planned. BioSante targets mid-2011 for ...

BioSante gets good news on LibiGel FierceBiotech

BioSante's (Nasdaq: BPAX) CEO Pleased With the Progress of LibiGel(R) Phase ... CNNMoney.com (press release)

BioSante Pharma Announces Positive LibiGel Safety Data In Phase III Program RTT News



all 31 news articles »

Zydus applies for Phase II & III H1N1 vaccine trials

Economic Times

Zydus now plans to conduct the Phase-II and Phase - III clinical trials in Ahmedabad, Bangalore, Jaipur and Pune. The company will be manufacturing the ...

First phase of H1N1 vaccine trial over Indian Express

Indigenous swine flu vaccine soon to be available bolohealth.com

Indian made H1N1 vaccine is on the way The First Reporter

TopNews  - RTT News

all 26 news articles »

EnteroMedics retools, refocuses to win FDA approval

MedCity News

The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebo. ...

Santarus Reports Fourth Quarter and Full Year 2009 Financial Results

MarketWatch (press release)

Enrollment in the European Phase III study for budesonide MMX(R) was completed in December 2009 and we expect to complete enrollment in the US Phase III ...

Q4 2009 Earnings Call Transcript Seeking Alpha (blog)



all 74 news articles »

Pro-Pharmaceuticals Reports Full Year and Fourth Quarter 2009 Financial Results

MarketWatch (press release)

"We plan to initiate a Phase III clinical trial for late stage colorectal cancer patients as soon as we raise sufficient funds. In addition, the Company is ...



and more »

BioSante Secures $18 Million in Registered Direct Offering

Trading Markets (press release)

BioSante said that proceeds from the transaction will be used for general corporate purposes, including continuing funding of BioSante's LibiGel Phase III ...



and more »

Tioga Nabs $18M from VCs for Phase III Irritable Bowel Studies

BioWorld Online

Urso said the FDA has moved away from IBS pain relief endpoints used in the past, which is why Tioga's Phase III trial will focus on the responder analysis ...

Tioga raises $18M for Phase III clinical trial FierceBiotech



all 21 news articles »

Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical ...

istockAnalyst.com (press release)

The new programme on Lu AA21004 will consist of four clinical phase III studies including approximately 2000 patients with moderate to severe depression in ...

Danish Lundbeck to launch two depression drugs in phase III Trading Markets (press release)



all 11 news articles »